Apolipoprotein-B synthesis inhibitors
    1.
    发明授权
    Apolipoprotein-B synthesis inhibitors 失效
    载脂蛋白-B合成抑制剂

    公开(公告)号:US5929075A

    公开(公告)日:1999-07-27

    申请号:US817247

    申请日:1997-04-09

    摘要: The present invention provides novel compounds of formula ##STR1## the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof, wherein A and B taken together form a bivalent radical of formula:--N.dbd.CH-- (a), --CH.dbd.N-- (b), --CH.sub.2 --CH.sub.2 -- (c), --CH.dbd.CH-- (d), --C(.dbd.O)--CH.sub.2 -- (e), --CH.sub.2 --C(.dbd.O)-- (f); R.sup.1 is hydrogen, C.sub.1-6 alkyl, or halo; R.sup.2 is hydrogen or halo; R.sup.3 is hydrogen; C.sub.1-8 alkyl; C.sub.3-6 cycloalkyl or C.sub.1-8 alkyl substituted with hydroxy, oxo, C.sub.3-6 cycloalkyl or aryl. Het is five- or six-membered optionally substituted heterocyclic ring. The use as a medicine, especially as a lipid lowering agent is disclosed as well as pharmaceutical compositions and processes for preparing compounds and compositions.

    摘要翻译: PCT No.PCT / EP95 / 04111 Sec。 371日期1997年04月9日 102(e)日期1997年4月9日PCT 1995年10月19日PCT PCT。 第WO96 / 13499号公报 日期:1996年5月9日本发明提供了新型式的化合物N-氧化物,其立体化学异构形式及其药学上可接受的酸加成盐,其中A和B一起形成下式的二价基团-N = CH- (a)中,-CH = N-(b),-CH 2 -CH 2 - (c),-CH = CH-(d),-C(= O)-CH 2 - (e) O) - (f); R1是氢,C1-6烷基或卤素; R2是氢或卤素; R3是氢; C 1-8烷基; C 3-6环烷基或被羟基,氧代,C 3-6环烷基或芳基取代的C 1-8烷基。 Het是五或六元任选取代的杂环。 公开了作为药物的使用,特别是作为降脂剂的用途以及用于制备化合物和组合物的药物组合物和方法。

    Triazolones as apolipoprotein-B synthesis inhibitors
    2.
    发明授权
    Triazolones as apolipoprotein-B synthesis inhibitors 失效
    三唑酮作为载脂蛋白-B合成抑制剂

    公开(公告)号:US5922718A

    公开(公告)日:1999-07-13

    申请号:US930847

    申请日:1997-10-07

    摘要: The present invention concerns novel compounds of formula (I). ##STR1## wherein R.sup.1 is C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl or C.sub.1-6 alkyl substituted with C.sub.3-7 cycloalkyl; R.sup.2 is hydrogen or C.sub.1-6 alkyl; Alk represents C.sub.1-3 alkanediyl; --A-- represents a bivalent radical of formula --CH.dbd.CH--N.dbd.CH-- (a), --N.dbd.CH--N.dbd.CH-- (b), --CH.dbd.N--N.dbd.CH-- (c), --CH.dbd.CH--CH.dbd.N-- (d); in said bivalent radicals a hydrogen atom may be replaced by C.sub.1-6 alkyl; and Ar is unsubstituted phenyl; phenyl substituted with up to two substituents selected from halo, C.sub.1-6 alkyl or C.sub.1-6 alkyloxy; unsubstituted naphthyl; or naphthyl substituted with up to two substituents selected from halo, C.sub.1-6 alkyl or C.sub.1-6 alkyloxy; the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof. The present invention further comprises the pharmaceutical compositions comprising compounds of formula (I), the preparation thereof as well as the use as a medicine in the treatment of hyperlipidemia.

    摘要翻译: PCT No.PCT / EP96 / 01585第 371日期1997年10月7日第 102(e)日期1997年10月7日PCT 1996年4月12日PCT PCT。 WO96 / 33193 PCT出版物 日期:1996年10月24日本发明涉及新的式(I)化合物。 其中R 1是C 1-10烷基,C 3-7环烷基或被C 3-7环烷基取代的C 1-6烷基; R2是氢或C1-6烷基; Alk表示C1-3烷二基; -A-表示式-CH = CH-N = CH-(a),-N = CH-N = CH-(b),-CH = NN = CH-(c),-CH = CH -CH = N-(d); 在所述二价基团中,氢原子可被C 1-6烷基取代; 和Ar是未取代的苯基; 被至多两个选自卤素,C 1-6烷基或C 1-6烷氧基的取代基取代的苯基; 未取代的萘基; 或被至多两个选自卤素,C 1-6烷基或C 1-6烷氧基的取代基取代的萘基; 其立体化学异构形式及其药学上可接受的酸加成盐。 本发明还包含包含式(I)化合物,其制备方法以及用作治疗高脂血症药物的药物组合物。